Dolutegravir Tetra-O-acetyl- O-Beta-D-glucoside

Ref. TR-D528830

Informations sur le produit

• Nom: Dolutegravir Tetra-O-acetyl- O-Beta-D-glucoside
• Synonymes: (2R,3R,5R,6S)-2-(Acetoxymethyl)-6-(((4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate

Description

Applications Dolutegravir Tetra-O-acetyl- O-β-D-glucoside is an intermediate in the synthesis of Dolutegravir O-β-D-Glucoside (D528815) which is a metabolite of Dolutegravir (D528800); a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011)

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 749.67
• Formule: C₃₄H₃₇F₂N₃O₁₄
• Couleur/Forme: Pale Brown Foam
• InChI: InChI=1S/C34H37F2N3O14/c1-15-8-9-47-25-13-38-12-22(32(45)37-11-20-6-7-21(35)10-23(20)36)27(44)29(26(38)33(46)39(15)25)53-34-31(51-19(5)43)30(50-18(4)42)28(49-17(3)41)24(52-34)14-48-16(2)40/h6-7,10,12,15,24-25,28,30-31,34H,8-9,11,13-14H2,1-5H3,(H,37,45)/t15-,24-,25+,28-,30?,31-,34+/m1/s1
• Code InChI: InChIKey=XSQUCXPUDIKVPN-WZQOJGDESA-N
• SMILES: CC(=O)OC[C@H]1O[C@@H](Oc2c3n(cc(C(=O)NCc4ccc(F)cc4F)c2=O)C[C@@H]2OCC[C@@H](C)N2C3=O)[C@H](OC(C)=O)C(OC(C)=O)[C@@H]1OC(C)=O